Every product that touches a patient in a hospital has, at some point, passed through a room most clinicians never see. The value analysis committee decides which gloves, catheters, pads, staplers and monitors reach the bedside, and which do not. Done well, it is one of the most useful clinical safeguards a hospital has.

This piece describes what a good review looks like and how frontline clinicians can take part in it. It sits between two longer articles in this series. Part 1, The Committee That Guards the Contract, looked at how purchasing contracts shape the committee’s work. Part 2, On Contract Is Not Clinically Vetted, looks at what happens when the contract arrives before the clinical question. Here the aim is simpler: to set out the standard both of those pieces measure against.

Why value analysis exists

Value analysis puts clinical judgment, safety and cost into a single decision, made once, on the record. Before it existed, products often reached the floor because one surgeon asked, one buyer found a lower price, or one sales visit went well. Nobody weighed all three at once.

The Association of Healthcare Value Analysis Professionals (AHVAP) describes the work as an “evidenced-based systematic approach” to reviewing products, equipment, technology and services, judged on clinical efficacy, appropriate use and safety alongside financial value. That is the right order: whether it works and whether it is safe come first, and price is weighed against them, not ahead of them.

Good committees earn their keep. They retire duplicate products, catch devices that look cheaper but cost more in use, and give clinicians a fair hearing for something better. The rest of this piece describes how they do it.

The four questions a good review answers

Every sound review, whatever the product, answers the same four questions in writing.

1. Does it work for our patients? Not for patients in general, but for this hospital’s mix: its case types, body sizes, ages and acuity. Published evidence is the start; the hospital’s own outcome data is the check.
2. Is it safe for patients and for staff? Patient safety is the obvious half. The other half is the people who handle the product every day: lifting, turning, opening, reprocessing. A device that is safe for the patient but injures the nurse is not safe.
3. What does it cost over its whole life? The unit price is one line. Waste, staff time, injuries, reprocessing, storage, disposal and outcomes are the rest of the bill (see total cost of ownership, below).
4. Can staff use it correctly every time? A product that works in the hands of an expert but fails on a busy night shift will fail. Training needs, packaging, labeling and fit with existing equipment belong in the review.

When all four answers are written down, the decision explains itself. When one is missing, that is usually where the trouble starts later.

Who should be at the table

A good committee seats the people who will live with the decision, because each sees a cost the others cannot.

The seats matter less than the voting. When clinical and safety members have a real say, rather than a courtesy review after the price is set, the four questions above get answered in the right order.

Total cost of ownership, in plain terms

The cheapest unit is often not the cheapest choice. Total cost of ownership adds up everything a product costs from the loading dock to the trash: the purchase price, plus what it takes to use it, plus what happens when it goes wrong.

A simple worked example, with illustrative numbers only. Two single-use products do the same job:

Product A wins the price comparison and loses the cost comparison. Over a year of cases, the gap is real money, and the staff time it frees goes back to patients. Injuries, infections and reprocessing can be added the same way when they apply.

The committee’s job is to ask for these numbers before the decision, not discover them after. For surgical positioning products, our cost-of-ownership calculator runs this arithmetic on a facility’s own case volume and EHR-measured times.

What a fair product trial looks like

A fair trial is designed before it starts, so the result cannot be argued into shape afterward.

• Success criteria set in advance. Written down and agreed before the first case: what counts as better, worse or the same.
• The right units. The product is tried where it will actually be used, by the people who will use it.
• Enough cases. A handful of uses on one shift says little. The trial runs long enough to cover different staff, case types and days.
• Both products judged the same way. If the current product is the comparison, it is scored on the same form, in the same period.
• Training for everyone. Staff on every shift get the same introduction, so the trial measures the product, not who happened to be shown how to use it.
• Honest feedback forms. Short, specific questions tied to the success criteria, with room for comments. Results are shared with the people who filled them in.
• A decision date. The trial ends on a set day and the committee decides within a set time after it.

Timelines, written decisions and second looks

A review that never ends is a decision by default. Good committees make their process visible and predictable.

• A published calendar. Clinicians know when the committee meets, how to get on the agenda and how long a typical review takes.
• A clock on each stage. Intake, evidence review, trial and decision each have a target time, and requests that miss it are flagged rather than left to drift.
• Written decisions with reasons. Approved, declined or deferred, the requester gets the answer and the reasons in writing, tied to the four questions.
• A way back in. New evidence, a safety event, a recall or a change in price reopens the question. A no today is not a no forever.
• A look after adoption. Six or twelve months after a change, the committee checks whether the expected savings and outcomes actually arrived.

Transparency protects the committee as much as the clinicians. A decision with written reasons is easy to defend; one without them invites the suspicion that something other than the evidence decided it.

How frontline clinicians can take part

The people who use a product every day are the committee’s best source of evidence, and most committees want to hear from them. A few habits make that input count.

1. Learn the front door. Find out who chairs the committee, how requests are submitted and when it meets. Many hospitals have a short request form.
2. Bring a problem, not just a product. Start with what is going wrong: an injury, a delay, a failure, a workaround. A clear problem gets a review; a brand name alone often does not.
3. Gather the evidence early. Published studies, the hospital’s own incident or injury reports, case counts and the time a task takes now.
4. Find allies across disciplines. A request backed by nursing, the surgeon, infection prevention and employee health carries more weight than one voice.
5. Offer to help with the trial. Volunteer to set criteria, train colleagues and collect feedback. It keeps the trial fair and shows the committee the request is serious.
6. Ask for the decision in writing. Whatever the outcome, the reasons tell you what evidence would change it.
7. Report back after a change. If a new product helps or hurts, tell the committee. That feedback is how the next review gets better.

Closing

At its best, value analysis is clinical stewardship: the right product, judged by the people who use it, at a cost the hospital can sustain. The four questions, the right people at the table, an honest count of total cost, a fair trial and a written decision are not extra steps. They are what make the answer trustworthy.

Most committees are staffed by people who want exactly that. The harder question is what happens when a decision has already been shaped before the committee sees it, by a purchasing contract signed elsewhere. That is the subject of Part 2, On Contract Is Not Clinically Vetted.

Sources

• AHVAP Mission and Statement of Purpose
• Applying the AHVAP Standards of Practice (GHX Summit, May 2026)
• NIOSH: Evaluation of Different Patient Transfer Devices in Reducing Biomechanical Exposures Among Professional Caregivers
• AORN Ergonomic Tool 1: Lateral Transfer of a Patient from a Stretcher to an OR Bed (CDC Stacks)

The cost example in this piece uses illustrative numbers, not data from any hospital or product.